ZA200500618B - Combinations of drugs for the treatment of neoplasms - Google Patents

Combinations of drugs for the treatment of neoplasms

Info

Publication number
ZA200500618B
ZA200500618B ZA200500618A ZA200500618A ZA200500618B ZA 200500618 B ZA200500618 B ZA 200500618B ZA 200500618 A ZA200500618 A ZA 200500618A ZA 200500618 A ZA200500618 A ZA 200500618A ZA 200500618 B ZA200500618 B ZA 200500618B
Authority
ZA
South Africa
Prior art keywords
neoplasms
drugs
combinations
treatment
Prior art date
Application number
ZA200500618A
Other languages
English (en)
Inventor
Alexis Borisy
Curtis Keith
Michael A Foley
Brent R Stockwell
Debra A Gaw
Nichols M James
Margaret S Lee
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of ZA200500618B publication Critical patent/ZA200500618B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200500618A 2002-07-11 2005-01-21 Combinations of drugs for the treatment of neoplasms ZA200500618B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39523302P 2002-07-11 2002-07-11

Publications (1)

Publication Number Publication Date
ZA200500618B true ZA200500618B (en) 2006-08-30

Family

ID=30115841

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500618A ZA200500618B (en) 2002-07-11 2005-01-21 Combinations of drugs for the treatment of neoplasms

Country Status (15)

Country Link
US (2) US20040116407A1 (xx)
EP (1) EP1545544A2 (xx)
JP (1) JP2005536509A (xx)
CN (1) CN1681511A (xx)
AU (1) AU2003256511A1 (xx)
BR (1) BR0312597A (xx)
CA (1) CA2492059A1 (xx)
HR (1) HRP20050115A2 (xx)
IL (1) IL166217A0 (xx)
IS (1) IS7691A (xx)
MX (1) MXPA05000485A (xx)
NO (1) NO20050204L (xx)
RU (1) RU2005103610A (xx)
WO (1) WO2004006842A2 (xx)
ZA (1) ZA200500618B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
FR2842423B1 (fr) * 2002-07-18 2005-07-08 Centre Nat Rech Scient Composes a activite anti-parasitaire et medicaments les renfermant
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1599606A1 (en) * 2003-03-03 2005-11-30 Arizona Board of Regents on behalf of The University of Arizona Protein tyrosine phosphatase - prl-1 a a marker and therapeutic target for pancreatic cancer
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
EP1667680A4 (en) * 2003-08-29 2008-10-08 Aton Pharma Inc COMBINED METHODS OF TREATING CANCER
BRPI0414568A (pt) * 2003-09-18 2006-11-07 Combinatorx Inc combinações de drogas para o tratamento de neoplasmas
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
CA2547972A1 (en) * 2003-11-24 2005-06-09 Georgia State University Research Foundation, Inc. Fused ring dicationic anti-protozoan agents and their prodrugs
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
NZ555370A (en) * 2004-12-15 2010-03-26 Sigma Tau Ind Farmaceuti Combinations of therapeutic agents for treating cancer
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
AU2006239896A1 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
EP1877047A2 (en) * 2005-05-02 2008-01-16 The Regents of the University of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
BRPI0520686A2 (pt) * 2005-11-16 2009-05-19 Univ Mexico Nacional Autonoma uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
WO2008016890A1 (en) * 2006-07-31 2008-02-07 Abbott Laboratories Antitumorigenic drug combination
WO2009029656A1 (en) * 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
RU2519200C2 (ru) * 2008-10-01 2014-06-10 Новартис Аг Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений
CA2758856A1 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
US8809299B2 (en) * 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer
CN105030785B (zh) * 2015-06-30 2017-11-10 上海交通大学 Promethazine在制备抗肝癌和/或结肠癌和/或肺癌产品中的应用
JP7059444B2 (ja) * 2018-05-04 2022-04-25 コリア インスティチュート オブ レディオロジカル アンド メディカル サイエンシズ アリピプラゾールを有効成分として含有する放射線敏感性増進用組成物
CN113264925A (zh) * 2020-02-14 2021-08-17 上海美悦生物科技发展有限公司 一种杂环化合物及其制备方法和用途
CN113304155B (zh) * 2021-05-24 2023-03-24 四川大学华西医院 一种抗肿瘤的药物组合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
IS7691A (is) 2005-02-09
RU2005103610A (ru) 2005-08-27
HRP20050115A2 (en) 2005-10-31
MXPA05000485A (es) 2005-04-19
IL166217A0 (en) 2006-01-15
WO2004006842A2 (en) 2004-01-22
US20040116407A1 (en) 2004-06-17
CN1681511A (zh) 2005-10-12
AU2003256511A1 (en) 2004-02-02
WO2004006842A3 (en) 2004-05-27
US20070099905A1 (en) 2007-05-03
CA2492059A1 (en) 2004-01-22
JP2005536509A (ja) 2005-12-02
EP1545544A2 (en) 2005-06-29
NO20050204L (no) 2005-04-08
BR0312597A (pt) 2005-05-10

Similar Documents

Publication Publication Date Title
ZA200500618B (en) Combinations of drugs for the treatment of neoplasms
IL174232A0 (en) Combinations of drugs for the treatment of neoplasms
AU2003249244A1 (en) Methods for the treatment of neoplasms
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
GB0316912D0 (en) Therapeutic treatment
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
GB0320806D0 (en) Therapeutic treatment
EP1651211A4 (en) COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASMS
AU2003251904A8 (en) Combinations of drugs for the treatment of neoplasms
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2003215150A8 (en) Therapeutic compounds
GB0329275D0 (en) Therapeutic treatment
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
EP1485077A4 (en) DRUGS COMBINATION THERAPY
GB0327493D0 (en) Treatment medicament
GB0208392D0 (en) Therapeutic compounds
GB0325957D0 (en) The treatment of pain
GB0329357D0 (en) Treatment of materials
SI1485057T1 (sl) Derivati azaspiro spojin za zdravljenje bolecine
GB0203173D0 (en) The treatment of neurodegenerative disease
SI1485352T1 (en) Azaspiro compounds for the treatment of pain